Abstract
The influence of human anti-OC125 antibodies formed after multiple infusions of OC125 F(ab′)2 fragments on the apparent levels of CA 125 measured with four different tests were examined in two ovarian cancer patients. With the homologous Assay 1, involving only OC125 antibodies, false increases of CA 125 values were observed after infusion of OC125 fragments, which completely covered real CA 125. In contrast, with Assay 2, 3 and 4, which involve no OC125 antibodies as capture antibodies, only slight false increases occurred in the presence of very high anti-OC125 antibody concentrations. Interference was eliminated by addition of non-specific murine IgG in Assay 2 and 4, but not in Assay 1 and 3 indicating that the false increases in Assay 1 and 3 were caused by anti-idiotypic anti-OC125 antibodies. In the presence of elevated real CA 125, with Assay 2 and to a considerably lesser degree with Assay 4, an inhibitory effect of anti-OC125 antibodies became evident leading to false decreases of CA 125 values. In Assay 4 reduction of assay response was eliminated by addition of non-specific murine IgG. The results confirm that all available CA 125 tests are influenced by interference with human anti-OC125 antibodies. Thus, CA 125 levels in patients who have been treated with OC125 fragments should be interpreted with care.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bast RC, Freeney M, Lazarus H, Nadler LM, Colvin RB, Knapp RC (1981) Reactivity of monoclonal antibody with human ovarian carcinoma. J Clin Invest 68:1331–1337
Bast RC, Klug TL, St. John E, Jenison E, Niloff JM, Lazarus H, Berkowitz RS, Leavitt T, Griffiths CT, Parker L, Zurawski VR, Knapp RC (1983) A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 309:883–887
Boscato LM, Stuart MC (1988) Heterophilic antibodies: a problem for all immunoassays. Clin Chem 34:27–33
Brökelmann J, Bockisch A, Vogel J, Reinsberg J, Oehr P, Biersack HJ, Krebs D (1989) Immunoscintigraphy using OC 125 antibodies in the management of ovarian cancer. Arch Gynecol Obstet 244:193–206
Jerne NK, Roland J, Cazenave PA (1982) Recurrent idiotopes and internal images. EMBO J 1:243–247
Kabawat SE, Bast RC, Welch WR, Knapp RC, Colvin RB (1983) Immunopathologic characterization of a monoclonal antibody that recognizes common surface antigens of human ovarian tumors of serous, endometrioid, and clear cell types. Am J Clin Pathol 79:98–104
Klug TL, Green PJ, Zurawski VR, Davis HM (1988) Confirmation of a false positive result in CA 125 immunoradiometric assay caused by human anti-idiotypic immunoglobulin. Clin Chem 34:1071–1076
Krantz MJ, MacLean G, Longenecker BM, Suresh MR (1988) A radioimmunoassay for CA 125 employing two new monoclonal antibodies (Abstract). J Cell Biochem Suppl 12E:139
Muto MG, Lepisto EM, Van den Abbeele AD, Knapp RC, Kassis AI (1989) Influence of human antimurine antibody on CA 125 levels in patients with ovarian cancer undergoing radioimmunotherapy or immunoscintigraphy with murine monoclonal antibody OC 125. Am J Obstet Gynecol 161:1206–1212
Niloff JM, Bast RC, Schaetzl EM, Knapp RC (1985) Predictive value of CA 125 antigen levels in second-look procedure of ovarian cancer. Am J Obstet Gynecol 151:981–986
O'Brien TJ, Raymond LM, Bannon GA, Ford DH, Hardardottir H, Miller FC, Quirk JG (1991) New monoclonal antibodies identify the glycoprotein carrying the CA 125 epitope. Am J Obstet Gynecol 165:1857–1864
Perkins AC, Powell MC, Pimm MV, Wastie ML, Symonds EM, Baldwin RW (1986) Immunoscintigraphy of gynecological tumors. In: Winkler C (ed) Nuclear medicine in clinical oncology — current status and future aspects. Springer, Berlin Heidelberg New York, pp 177–186
Reinsberg J (1993) Idiotypic cascades after MAb OC 125 application. Hybridoma (in press)
Reinsberg J, Nocke W (1993) Falsely low results in CA 125 determination due to anti-idiotypic antibodies induced by infusion of131I-F(ab′)2 fragments of the OC 125 antibody. Eur J Clin Chem Clin Biochem 31:323–327
Reinsberg J, Heydweiller A, Wagner U, Pfeil K, Oehr P, Krebs D (1990) Evidence for interaction of human anti-idiotypic antibodies with CA 125 determination in a patient after radioimmunodetection. Clin Chem 36:164–167
Reinsberg J, Schultes B, Wagner U, Krebs D (1993a) Monitoring of CA 125 in serum of ovarian cancer patients after administration of131I-F(ab′)2 fragments of the OC 125 antibody. Clin Chem 39:891–896
Reinsberg J, Wagner U, Volkmuth S, Krebs D (1993b) Antikörper-Induktion durch Gabe von OC 125-Fragmenten und ihre Bedeutung für den Nachweis von CA 125. Arch Gynecol Obstet (in press)
Turpeinen U, Lehtovirta P, Alfthan H, Stenman UH (1990) Interference by human antimouse antibodies in CA 125 assay after immunoscintigraphy: Anti-idiotypic antibodies not neutralized by mouse IgG but removed by chromatography. Clin Chem 36:1333–1338
Vergote IB, Börmer OP, Abeler VM (1987) Evaluation of serum CA 125 levels in the monitoring of ovarian cancer. Am J Obstet Gynecol 157:88–92
Wagner U, Reinsberg J, Krebs D (1990) Versuch einer Immuntherapie des Ovarialkarzinomes durch Idiotypen-Vakzination. Geburtshilfe Frauenheilkd 50:785–788
Wagner U, Oehr P, Reinsberg J, Schmidt S, Schlebusch H, Werner A, Krebs D (1992) Immunotherapy of advanced ovarian carcinomas by the activation of the idiotypic network. Biotech Therapeutics 3:81–89
Zweig MH, Csako G, Benson CC, Weintraub BD, Kahn BB (1987) Interference by anti-immunoglobulin G antibodies in immunoradiometric assays for thyrotropin involving mouse monoclonal antibodies. Clin Chem 33:840–844
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Reinsberg, J., Wagner, U. & Krebs, D. False changes in CA 125 levels in ovarian cancer patients after infusion of OC125 fragments for diagnostic and therapeutic purpose. Arch Gynecol Obstet 255, 9–18 (1994). https://doi.org/10.1007/BF02390669
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02390669